ATP5IF1 and anemia: The observation that splenic erythroid cells can overcome ATPIF1 deficiency via glycolytic/PPP activation suggests that pharmacological agents targeting these pathways (e.g., PPP activators like metformin or glycolytic enhancers) could mitigate anemia in patients with mitochondrial dysfunction.